EARLY POSTMENOPAUSAL BONE LOSS AND INTERMITTENT CYCLICAL ETIDRONATE THERAPY

Citation
I. Fogelman et G. Blake, EARLY POSTMENOPAUSAL BONE LOSS AND INTERMITTENT CYCLICAL ETIDRONATE THERAPY, Reviews in contemporary pharmacotherapy, 9(4), 1998, pp. 245-254
Citations number
26
Categorie Soggetti
Pharmacology & Pharmacy
ISSN journal
09548602
Volume
9
Issue
4
Year of publication
1998
Pages
245 - 254
Database
ISI
SICI code
0954-8602(1998)9:4<245:EPBLAI>2.0.ZU;2-Y
Abstract
The bisphosphonates have increasingly been recognized as having an imp ortant role to play in the treatment of established osteoporosis, part icularly when hormone replacement therapy cannot be used. However, the ir role in the prevention of bone loss, and in particular their effica cy in the early postmenopausal period, is not clear. Recently, double- blind placebo-controlled studies using intermittent cyclical therapy w ith etidronate (ICT-etidronate) have been published and these are revi ewed. It is shown that this treatment is highly effective in preventin g bone loss throughout the skeleton, and in particular at the clinical ly relevant sites of spine and femur. Treatment was well tolerated and the incidence of adverse effects was comparable to that found in the placebo-treated patients.